DOCSLIB.ORG

Uterine Sarcomasarcoma Chapterchapter 55

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Uterine Sarcomasarcoma Chapterchapter 55 UterineUterine SarcomaSarcoma ChapterChapter 55 FredFred UeUelland,and, MMDD Division of Gynecologic Oncology University of Kentucky UniveUniverrsitysity ofof KentuKentucckyky AnnualAnnual NewNew CancersCancers 140 128 120 100 Uterus 84 82 Ovary 80 Cervix 60 Vulva 42 40 Other 20 13 0 UniveUniverrsitysity ofof KentuKentucckyky AnnualAnnual RecurrentRecurrent CancersCancers 20 20 17 15 15 Uterus 10 Ovary 10 Cervix Other 5 0 OveOverrviewview 33--5%5% ofof allall uterineuterine mmalignancialignancieess 22 perper 100,000100,000 wwoomemenn inin UUSSAA AriseArise frfromom endendoommetrialetrial ssttrromaoma,, glaglanndsds oror uterineuterine mmuscusclle.e. OOttherher memesencsenchymahymall tutumormorss areare rararree 2020 yearyearss afterafter pelpelvvicic radiotheraradiotherappyy BlackBlack wwomeomenn mmoorree ccoommmmonon ClassifClassifiicaticatioonn OberOber,, 19591959 HHoomologousmologous – Pure Stromal sarcoma (endolymphatic stromal myosis) Leiomyosarcom Angiosarcoma Fibrosarcoma – Mixed Carcinosarcoma ClassifClassifiicaticatioonn OberOber,, 19591959 HeterologousHeterologous – Pure Rhabdomyosarcom Chondrosarcoma Osteosarcoma Liposarcoma – Mixed Mixed mullerian tumor (MMT) ClassifClassifiicaticatioonn SGOSGO EndEndoorsedrsed LeiLeiomomyoyossarcarcoommaa EndEndoomemettrialrial StrStromomalal SaSarrccomomaa MixedMixed hhoomologousmologous MullerMulleriianan SaSarrcocomamass ((cacarrcinosarccinosarcomaoma)) MixedMixed heterologousheterologous MullerMulleriianan SaSarrcocomamass (m(mixedixed mmesodeesodermrmalal sasarrccomaoma)) OtherOther uterinuterinee sasarrcocomamass LeLeiiomyosomyosaarcomarcoma MetastaticMetastatic PotePotenntialtial Mitoses Atypia Diagnosis Metastatic 1-4 Any Myoma Very low 5-9 None Myoma with high mitotic Very low activity 5-9 Gr 1 Smooth muscle tumor of Low uncertain malignant potential 5-9 Gr 2,3 LMS Moderate ≥10 Gr 1 LMS High ≥ 10 Gr 2,3 LMS Very high UterineUterine SSaarrcocomama Endometrial stromal sarcoma – Age 45 – Ifosfamide Leiomyosarcoma – Age 55 – Adriamycin/Ifosfamide – Gemcitabine/Taxotere (GOG #131-G) Mixed mullerian tumor – Age 65 – Ifosfamide v. Ifos/Taxol (GOG #161) – Carbo/Taxol (GOG #232-B) UterineUterine SarcomaSarcoma EndometriaEndometriall CancerCancer RiskRisk FactorsFactors Anovulation-PCO Early menarche Exogenous estrogen Late menopause Endogenous estrogen Diabetes Family history Hypertension Nulliparity Granulosa cell tumors Age History of breast of Infertility colon cancer Tamoxifen Menstrual irregularities EndometrialEndometrial CaCanncercer RelativeRelative RisRiskk ObesityObesity (20-50 lb) 33 ObesityObesity (>50 lb) 1010 NulliparityNulliparity 22--33 LateLate mmenopauseenopause 2.42.4 DiabeteDiabetess memellitusllitus 2.82.8 TTamamoxifenoxifen 7.57.5 UnopposedUnopposed ERTERT 9.59.5 PresentationPresentation PostmenoPostmenoppausalausal BleedBleediingng Etiologic Factor Lahey Clinic (%) Mayo Clinic (%) ERT 27 27 Atrophy 23 20 Cancer 19.5 18 EAC 13 16 Cervix 4 1 Other 2.5 1 Atrophic vaginitis 10 9 Endometrial polyps 7 23 Cervical polyps 6.5 14 EndometriaEndometriall CancerCancer withwith PMBPMB Age Total cases Total # EAC % Cancer <50 34 0 0 50-59 161 15 9.3 60-69 92 15 16.3 70-79 43 12 27.9 >80 5 3 60 AtypicalAtypical EnEnddometrialometrial CellsCells EndometriaEndometriall CellsCells onon PapPap PostPostmenomenoppauaussalal Cells Total Hyperplasia Polyps Cancer Normal 74 9 1 1 (1%) + Atypical 22 0 1 5 (23%) Malignant 31 1 0 23 (74%) * +Ovarian cancer *2 cervical, 1 breast, 1 ovary, 19 endometrial cancers HormonesHormones aandnd EndometriaEndometriall CancerCancer HistopathologyHistopathology LeiomyosaLeiomyosarrcomacoma LeiomyosaLeiomyosarrcomacoma Bizarre nuclei LeiomyosaLeiomyosarrcomacoma UterineUterine SarcomaSarcoma UterineUterine SarcomaSarcoma UterineUterine SarcomaSarcoma LeiomysarLeiomysarccomaoma EndometrialEndometrial CaCanncercer HistologyHistology Histopathology Frequency Survival Endometrioid 66% 88% Adenoacanthoma 16% 91% Adenosquamous 5% 62% Papillary serous 8% 63% Clear cell 3% 43% Secretory 2% 89% SurvivalSurvival UterineUterine CaCanncercer StagingStaging anandd PrognosisPrognosis UterineUterine SSaarrcocomama FiveFive YearYear SurvivalSurvival (%)(%) StagStagee II SStatagege IIIIII ESSESS 9898 3838 LMSLMS 5050 88 MMTMMT 5050 <10<10 UterineUterine SSaarrcocomama %% FiveFive YeYeaarr SuSurrvivavivall Stage I Stage III ESS 98 38 LMS 50 8 MMT 50 <10 EndometrialEndometrial CaCanncercer % Distribution % Survival StageStage II 7733 8686 StageStage IIII 1122 6666 StageStage IIIIII 1122 4444 StageStage IIVV 33 1616 Petterson F, ed: Annual report on treatment Gyn Ca, vol 22; Stockholm, 1994, FIGO EndometrialEndometrial CaCanncercer FiveFive yearyear survival,survival, %% 86 90 80 70 66 60 Stage 1 50 44 Stage 2 40 Stage 3 30 Stage 4 16 20 10 0 EndometrialEndometrial CaCanncercer PrognosisPrognosis StageStage ((II--IV)IV) DepthDepth ofof invasioninvasion (A,B,(A,B,CC)) HistologicHistologic didiffferentiationferentiation (grade(grade 1,2,1,2,33)) HistologicHistologic cellcell ttypeype LLyymphvasculmphvasculaarr ssppaceace invasioninvasion PelvicPelvic ccytologyytology EndometrialEndometrial CaCanncercer ClinicalClinical StaStagging,ing, FIFIGGOO 19711971 Stage I Confined to corpus IA Sounds to ≤ 8cm IB Sounds to > 8cm Stage II Cervical involvement ECC, cervical biopsy, gross involvement Stage III Beyond uterus, confined to pelvis Stage IVA Bladder or rectal mucosa Stage IVB Extrapelvic metastasis EndometrialEndometrial CaCanncercer SurgicalSurgical StagingStaging,, 19881988 TotalTotal hysthysteerectrectomomy,y, bilabilatteraerall salpingosalpingo-- oopoophhorectorectomomyy PelvicPelvic washingwashing PelvicPelvic andand parparaa--aaoorticrtic lymlymphph nodenode ssamamplingpling OmOmententeectctomyomy,, upperupper abdabdomominalinal biopsiesbiopsies andand washingswashings forfor serousserous histologyhistology SurgSurgiicalcal RReeccommendatiommendationonss GGOOGG Manual,Manual, 19971997 PrognosticPrognostic notnot therapeutictherapeutic RRememovaloval ofof allall sususspiciouspicious nodesnodes RRememovaloval ofof oneone--halfhalf ofof pelvicpelvic nnoodesdes PAPA nodesnodes frfromom inferiorinferior mmesentesenteericric aarrterteryy toto ccoommmmonon iliiliaac,c, whwheenn indicatedindicated RecRecoommmemendednded forfor >> 50%50% invasioninvasion oror gradegrade 33 lesionslesions So,So, WhenWhen DDoo II DoDo thethe NNodes?odes? Balance between morbidity and utility – Lymphadenectomy is not risk free Preoperative grade – Accurate in 85% of cases Intraoperative evaluation – Frozen section 90% accurate for MM invasion Ueland’s “counsel” – IA gr 1,2 and IB gr 1 insufficient nodal risk to justify additional expense and morbidity EndometrialEndometrial CaCanncercer StageStage II StageStage II ConfConfiinedned toto uterusuterus IIAA LLimimitedited toto endendomeometritriuumm IBIB InnerInner ½½ mmyyoommetretriuiumm ICIC OuterOuter ½½ mmyyoommeettrriuiumm FiveFive yearyear susurrvivalvival (%)(%) StageStage II 88 90 78 80 67 70 60 IA 50 IB 40 IC 30 20 10 0 DifferentiationDifferentiation andand DepDeptthh Grade 1 Grade 2 Grade 3 IA 24 11 11 88% IB 53 45 35 88% IC 10 20 42 UterineUterine SarcomaSarcoma SurvivalSurvival 5-year survival Stage Cell Type S S+R R I MMS 52 % 48 % 29 % LMS 58 % 75 % 33 % ESS 47 % 88 % 50 % II-IV MMS 5 % 16 % 0 % LMS 0 % 13 % 0 % ESS 0 % 33 % 0 % UterineUterine SarcomaSarcoma %% SiteSite ofof RecurRecurrrenceence MMT-Ho MMT-He LMS N=165 N=134 N=57 Pelvis 9 12 7 Distant 33 46 56 None 58 42 37 LymphLymph NoNoddee MetastaMetastasseses ((%)%) EarEarllyy StageStage UterUteriinene SarcomaSarcoma Major, Cancer 1993 20 20 18 16 16 14 12 10 8 6 4 4 2 0 MMT MMT MMT MMT LMS Homo Hetero PelvicPelvic NNoodede MetastaMetastasseses ((%)%) StageStage II 18 18 16 14 12 Grade 1 9 10 Grade 2 8 Grade 3 6 3 4 2 0 FiveFive yearyear susurrvivalvival (%)(%) StageStage II 94 95 90 88 Grade 1 85 Grade 2 79 80 Grade 3 75 70 EndometrialEndometrial CaCanncercer StageStage IIII StageStage IIII CervicalCervical involvinvolveemmentent IIIIAA EndocervicalEndocervical glaglanndsds IIIIBB CervicalCervical strstromomaa EndometrialEndometrial CaCanncercer StageStage IIIIII StageStage IIIIII ExtraExtra--uterineuterine didisseeaasese IIIIIIAA Serosa,Serosa, adnexa,adnexa, ((++)) ccytologyytology IIIIIIBB VaginalVaginal memetastasttasaseess IIIIIICC LLyymphmph nodenode mmetaetasstasestases EndometrialEndometrial CaCanncercer StageStage IVIV StageStage IIVV Regional,Regional, distantdistant memetastasttasesases IVIVAA BowelBowel oror bladderbladder mumucosacosa IVIVBB DistantDistant memetastasttaseasess TreatmentTreatment PrimaryPrimary TrTreeatmentatment SurgerySurgery RadiotherapyRadiotherapy – Medically inoperable – 15% survival decrement each stage HoHormrmoneone thetherrapyapy – Only for grade 1 tumors in young women – Dilatation and curettage Confined to Uterus Extra-uterine disease Surgical staging Resection if possible (Omit LN if extrauterine ds) Stage I,II ESS Stage I,II other Stage IIIC, IV Stage III ESS Stage IIIA,B other No further therapy Whole pelvic XRT XRT (+ Hormone Tx for ESS) +/- Chemotherapy +/- Hormone therapy Recurrence No prior XRT Prior XRT Vaginal Pelvic Extra-pelvic Surgery +/- Chemotherapy +/- Hormone therapy Surgery Whole pelvic XRT WAR XRT +/- Chemotherapy +/- Hormone therapy ChemotherChemotheraapypy NCCNNCCN Guidelines,Guidelines, 20042004 Ifosfamide for carcinosarcoma Doxorubicin for LMS Single agent cisplatin, Taxol, Taxotere, Gemzar Hormone therapy – Megace – Provera – Tamoxifen – GnRH analogs
Load more

Recommended publications
  • Uterine Sarcomas: a Review
    ARTICLE IN PRESS YGYNO-973334; No. of pages: 9; 4C: 3, 6 Gynecologic Oncology xxx (2009) xxx–xxx Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Review Uterine sarcomas: A review Emanuela D'Angelo, Jaime Prat ⁎ Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Sant Antoni M. Claret, 167, 08025 Barcelona, Spain article info abstract Article history: Objective. Uterine sarcomas are rare tumors that account for 3% of uterine cancers. Their histopathologic Received 29 June 2009 classification was revised by the World Health Organization (WHO) in 2003. A new staging system has been Available online xxxx recently designed by the International Federation of Gynecology and Obstetrics (FIGO). Currently, there is no consensus on risk factors for adverse outcome. This review summarizes the available clinicopathological data Keywords: on uterine sarcomas classified by the WHO diagnostic criteria. Uterine sarcomas Methods. Medline was searched between 1976 and 2009 for all publications in English where the studied Leiomyosarcoma population included women diagnosed of uterine sarcomas. Endometrial stromal sarcoma fi Undifferentiated endometrial sarcoma Results. Since carcinosarcomas (malignant mixed mesodermal tumors or MMMT) are currently classi ed Adenosarcoma as metaplastic carcinomas, leiomyosarcomas remain the most common uterine sarcomas. Exclusion of Carcinosarcoma several histologic variants of leiomyoma, as well as “smooth muscle tumors of uncertain malignant potential,” frequently misdiagnosed as sarcomas, has made apparent that leiomyosarcomas are associated with poor prognosis even when seemingly confined to the uterus. Endometrial stromal sarcomas are indolent tumors associated with long-term survival. Undifferentiated endometrial sarcomas exhibiting nuclear pleomorphism behave more aggressively than tumors showing nuclear uniformity.
    [Show full text]
  • Role of Surgery in Gynaecological Sarcomas
    www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 26), pp: 2561-2575 Review Role of surgery in gynaecological sarcomas Valentina Ghirardi1,2, Nicolò Bizzarri1,2, Francesco Guida1,2, Carmine Vascone1,2, Barbara Costantini1,2, Giovanni Scambia1,2 and Anna Fagotti1,2 1Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome 00168, Italy 2Catholic University of Sacred Heart, Rome 00168, Italy Correspondence to: Anna Fagotti, email: [email protected] Keywords: sarcoma; uterine; cervical; ovarian; vulval Received: November 01, 2018 Accepted: January 19, 2019 Published: April 02, 2019 Copyright: Ghirardi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Gynaecological sarcomas account for 3-4% of all gynaecological malignancies and have a poorer prognosis compared to gynaecological carcinomas. Pivotal treatment for early-stage uterine sarcoma is represented by total hysterectomy. Whereas oophorectomy provides survival advantage in endometrial stromal sarcoma is still controversial. When the disease is confined to the uterus, systematic pelvic and para- aortic lymphadenectomy is not recommended. Removal of enlarged lymph-nodes is indicated in case of disseminated or recurrent disease, where debulking surgery is considered the standard of care. Fertility sparing surgery for uterine leiomyosarcoma is not supported by strong evidence, whilst available data on fertility sparing treatment for endometrial stromal sarcoma are more promising. For ovarian sarcomas, in the absence of specific data, it is reasonable to adapt recommendations existing for uterine sarcomas, also regarding the role of lymphadenectomy in both early and advanced stage disease.
    [Show full text]
  • Case Report Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma Without Capsular Involvement Implies a Local Route of Hematogenous Dissemination
    Hindawi Publishing Corporation Case Reports in Obstetrics and Gynecology Volume 2015, Article ID 950373, 5 pages http://dx.doi.org/10.1155/2015/950373 Case Report Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma without Capsular Involvement Implies a Local Route of Hematogenous Dissemination Monica Dandapani,1 Brandon-Luke L. Seagle,1 Amer Abdullah,1 Bryce Hatfield,2 Robert Samuelson,1 and Shohreh Shahabi3 1 Department of Obstetrics, Gynecology and Reproductive Biology, Western Connecticut Health Network, 24 Hospital Avenue, Danbury, CT 06810, USA 2Department of Pathology, Western Connecticut Health Network, 24 Hospital Avenue, Danbury, CT 06810, USA 3Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 03-2303, Chicago, IL 60611, USA Correspondence should be addressed to Shohreh Shahabi; [email protected] Received 2 March 2015; Accepted 9 April 2015 Academic Editor: Hao Lin Copyright © 2015 Monica Dandapani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Uterine sarcomas spread via lymphatic and hematogenous dissemination, direct extension, or transtubal transport. Distant metastasis often involves the lungs. Ovarian metastasis is uncommon. Here we present an unusual case of a large, high-grade uLMS with metastatic disease internal to both ovaries without capsular involvement or other abdominal diseases, and discovered in a patient with distant metastases to the lungs, suggesting likely hematogenous dissemination of uLMS to the ovaries in this case. Knowledge of usual uLMS metastases may influence surgical management in select cases.
    [Show full text]
  • Gynecologic Malignancies J
    Gynecologic Malignancies J. Brian Szender 31 March 2016 Outline • Female Cancer Statistics • Uterine Cancer • Adnexal Cancer • Cervical Cancer • Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial Cancer • Epidemiology and Risk Factors • Histology • Presentation • Diagnosis • Staging • Therapy • Early • Locally Advanced • Metastatic • Recurrent • Follow-Up • Future Therapy Epidemiology • 60,500 cases expected in 2016 • 25.3 per 100,000 women • 10,470 deaths expected in 2016 Epidemiology Increased Risk Decreased Risk • Age • Progestational Agents • Unopposed Estrogens • Oral Contraceptive Pills • Exogenous • Levonorgestrel IUS • Tamoxifen • Physical Activity • Obesity • Pregnancy • Genetic Risk • Breastfeeding • Lynch Syndrome • Cowden Syndrome Histology • Type I • Endometrioid, well differentiated • Less aggressive • Usually localized • Good Prognosis • Type II • Clear cell, papillary serous, MMMT, poorly differentiated • More aggressive • Likely to spread • Worse Prognosis Histology – Molecular Features Type I Type II • Diploid • Aneuploid • K-ras overexpression • K-ras overexpression • PTEN mutations • P53 overexpression • Microsatellite instability Clinical Presentation • Abnormal Uterine Bleeding • Postmenopausal Uterine Bleeding • Abnormal Vaginal Discharge • Endometrial cells on a pap smear • Bloating/pelvic pressure/pain (if advanced disease) Diagnosis • Ultrasound • Endometrial Biopsy • Hysteroscopy • Dilation and Curettage • Hysterectomy +/- BSO +/- Lymph node sampling Staging wikipedia Therapy – Early
    [Show full text]
  • NCCN Guidelines for Patients Uterine Cancer
    NCCN GUIDELINES FOR PATIENTS® 2021 Uterine Cancer Endometrial Carcinoma Uterine Sarcoma NATIONAL COMPREHENSIVE CANCER NETWORK Presented with support from: FOUNDATION Guiding Treatment. Changing Lives. Available online at NCCN.org/patients Ü Uterine Cancer It's easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer care options likely to have the best results 9 Based on treatment guidelines used by health care providers worldwide 9 Designed to help you discuss cancer treatment with your doctors NCCN Guidelines for Patients® Uterine Cancer, 2021 1 UterineAbout Cancer National Comprehensive Cancer Network® NCCN Guidelines for Patients® are developed by the National Comprehensive Cancer Network® (NCCN®) NCCN Clinical Practice NCCN Guidelines NCCN Guidelines in Oncology for Patients (NCCN Guidelines®) 9 An alliance of leading 9 Developed by doctors from 9 Present information from the cancer centers across the NCCN cancer centers using NCCN Guidelines in an easy- United States devoted to the latest research and years to-learn format patient care, research, and of experience 9 For people with cancer and education 9 For providers of cancer care those who support them all over the world Cancer centers 9 Explain the cancer care that are part of NCCN: 9 Expert recommendations for options likely to have the NCCN.org/cancercenters cancer screening, diagnosis, best results and treatment Free online at Free online at NCCN.org/patientguidelines NCCN.org/guidelines These NCCN Guidelines for Patients are based on the NCCN Guidelines® for Uterine Neoplasms, Version 3.2021 — June 3, 2021. © 2021 National Comprehensive Cancer Network, Inc.
    [Show full text]
  • What Is Uterine Sarcoma?
    cancer.org | 1.800.227.2345 About Uterine Sarcoma Overview and Types If you have been diagnosed with uterine sarcoma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Uterine Sarcoma? Research and Statistics See the latest estimates for new cases of uterine sarcoma and deaths in the US and what research is currently being done. ● Key Statistics for Uterine Sarcoma ● What's New in Uterine Sarcoma Research? What Is Uterine Sarcoma? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the body. To learn more about how cancers start and spread, see What Is Cancer?1 Uterine sarcoma is a rare cancer that starts in the muscle and supporting tissues of the uterus (womb). 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 About the uterus The uterus is a hollow organ, usually about the size and shape of a medium-sized pear: ● The lower end of the uterus, which extends into the vagina, is the cervix. ● The upper part of the uterus is the body, also known as the corpus. The body of the uterus has 3 layers. ● The inner layer or lining is the endometrium. ● The serosa is the layer of tissue coating the outside of the uterus. ● In the middle is a thick layer of muscle known as the myometrium. This muscle layer is needed to push a baby out during childbirth.
    [Show full text]
  • Treating Uterine Sarcoma If You've Been Diagnosed with Uterine Sarcoma, Your Cancer Care Team Will Discuss Your Treatment Options with You
    cancer.org | 1.800.227.2345 Treating Uterine Sarcoma If you've been diagnosed with uterine sarcoma, your cancer care team will discuss your treatment options with you. It's important to weigh the benefits of each treatment option against the possible risks and side effects. How is uterine sarcoma treated? These are the basic types of treatment for women with uterine sarcoma: ● Surgery for Uterine Sarcomas ● Radiation Therapy for Uterine Sarcomas ● Chemotherapy for Uterine Sarcomas ● Hormone Therapy for Uterine Sarcomas ● Targeted Therapy for Uterine Sarcomas Common treatment approaches A combination of treatments may be used to treat uterine sarcoma. The choice of treatment depends largely on thetype1 and stage of your cancer. Other factors might include your age, your overall health, whether you plan to have children, and your personal preferences. Most women with uterine sarcoma have surgery to remove the cancer. Radiation, chemotherapy, and hormone therapy are sometimes used to help lower the risk of the cancer coming back after surgery. These treatments may also be used for cancers that cannot be removed with surgery or when a woman can't have surgery because she has other health problems. ● Treatment for Uterine Sarcoma, by Type and Stage 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Who treats uterine sarcoma? Depending on your situation, you may have different types of doctors on your treatment team: ● A gynecologist: a doctor who specializes
    [Show full text]
  • A Rare Case of Epithelioid Trophoblastic Tumor: an Ultrasound Dilemma*
    A rare case of epithelioid trophoblastic tumor: An ultrasound dilemma* By April Anne P. Bolo-Paiso, MD, FPOGS and Melissa D.L. Amosco, MD, PhD, FPOGS, FPSUOG Department of Obstetrics and Gynecology, Philippine General Hospital, University of the Philippines-Manila ABSTRACT Gestational trophoblastic neoplasia (GTN) represents the malignant end of the gestational trophoblastic disease spectrum and includes the more common types, invasive mole (IM) and choriocarcinoma (CC) and the rare types, placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT). This is a case of a 42-year-old, G2P2 (2002) patient who complained of left lower quadrant pain and a 1 year history of amenorrhea. Urine pregnancy test done just prior to the surgery revealed positive result. Pre-operative diagnosis was abdominopelvic mass mass probably Sarcoma, ovarian new growth probably benign, right. Patient underwent exploratory laparotomy, adhesiolysis, bilateral internal iliac artery ligation, total hysterectomy with bilateral salpingo-oophorectomy, targeted biopsy, appendectomy, JP drain insertion under epidural anesthesia. Final histopathologic and immunohistochemical diagnosis is Epithelioid Trophoblastic Tumor. Differential diagnoses, diagnostics, and therapeutic options are presented, with focus on the description of sonographic features. Keywords: ultrasound, uterine sarcoma, epithelioid trophoblastic tumor INTRODUCTION The most common presenting symptom is vaginal bleeding. The serum level of beta HCG are usually slightly estational trophoblastic neoplasia represents the elevated (<2,500 mIU/mL) compared to those with malignant end of the gestational trophoblastic choriocarcinoma.7 Gdisease spectrum and includes the more common The role of transvaginal sonogram in gestational types, invasive mole and choriocarcinoma and the rare trophoblastic diseases cannot be over emphasized. types, placental site trophoblastic tumor (PSTT) and It has become the standard imaging protocol in the epithelioid trophoblastic tumor (ETT).
    [Show full text]
  • Japan Society of Gynecologic Oncology 2018 Guidelines for Treatment of Uterine Body Neoplasms
    J Gynecol Oncol. 2020 Jan;31(1):e18 https://doi.org/10.3802/jgo.2020.31.e18 pISSN 2005-0380·eISSN 2005-0399 Practice Guideline Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms Wataru Yamagami ,1 Mikio Mikami ,2 Satoru Nagase ,3 Tsutomu Tabata ,4 Yoichi Kobayashi ,5 Masanori Kaneuchi ,6 Hiroaki Kobayashi ,7 Hidekazu Yamada ,8 Kiyoshi Hasegawa ,9 Hiroyuki Fujiwara ,10 Hidetaka Katabuchi ,11 Daisuke Aoki 1 1Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan 2Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan Received: Aug 30, 2019 3Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan Accepted: Sep 5, 2019 4Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan 5Department of Obstetrics and Gynecology, Kyorin University Faculty of Medicine, Tokyo, Japan Correspondence to 6Department of Gynecology, Otaru General Hospital, Hokkaido, Japan Wataru Yamagami 7Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan Department of Obstetrics and Gynecology, 8Department of Gynecology, Miyagi Cancer Center, Miyagi, Japan Keio University School of Medicine, 35 9Department of Obstetrics and Gynecology, Dokkyo Medical University, Tochigi, Japan Shinanomachi, Shinjuku-ku Tokyo 160-8582, 10Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan Japan. 11Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan E-mail: [email protected] This article originally appeared in Japanese as Shikyu Taigan Chiryo Gaidorain 2018 Nen ban, ABSTRACT published by Kanehara, Tokyo, 2018. Copyright © 2020. Asian Society of The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published Gynecologic Oncology, Korean Society of in 2018.
    [Show full text]
  • Diagnosis, Treatment and Survival of Uterine Sarcoma: a Retrospective Cohort Study of 122 Cases
    MOLECULAR AND CLINICAL ONCOLOGY 13: 81, 2020 Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases TATIANE BURLE DE SIQUEIRA FERRONI PLENTZ, ELAINE CRISTINA CANDIDO, LAIS FLAUSINO DIAS, MARIA CAROLINA SZYMANSKI TOLEDO, DIAMA BHADRA VALE and JULIO CESAR TEIXEIRA Department of Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas, 13083‑881 São Paulo, Brazil Received January 24, 2020; Accepted August 11, 2020 DOI: 10.3892/mco.2020.2151 Abstract. The present study aimed to assess the diagnosis, Introduction treatment and follow‑up of uterine sarcoma cases. A retro‑ spective cohort study with 122 women recruited between 2001 Uterine sarcomas are a group of rare neoplasms, arising from and 2016 was performed. The data regarding epidemiology, myometrial or mesenchymal tissue, which represent 3 to 7% of clinical presentation, treatment and follow‑up were analyzed uterine cancer and tend to affect more elderly women, to exhibit based on the following histological types: Carcinosarcoma, aggressive behavior with fast‑growing, early distant metas‑ leiomyosarcoma, endometrial stromal sarcoma (ESS) and tasis and diagnosed in more advanced stages (1‑3). Surgery adenosarcoma. Statistical analysis included descriptive statis‑ is considered the basis of the treatment and other treatment tics, logistic regression and survival curves. The diagnosis of modalities, such as chemotherapy or radiation therapy, have uterine sarcoma exhibited an increasing trend of +1.2 new shown limited results (3,4). cases every 2 years (P=0.044) and comprised 10% of all Sarcomas exhibit diverse histopathology and some cases uterine cancer diagnoses. There were 47% carcinosarcomas, may have a Mullerian duct origin resulting in heterologous 22% leiomyosarcomas, 16% ESS and 14% adenosarcomas.
    [Show full text]
  • Primary Sarcoma of the Cervix: an Analysis of Patient and Tumor Characteristics, Treatment Patterns, and Outcomes
    J Gynecol Oncol. 2020 May;31(3):e25 https://doi.org/10.3802/jgo.2020.31.e25 pISSN 2005-0380·eISSN 2005-0399 Original Article Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes Ashley Albert ,1 Anna Lee ,2 Robert Allbright ,1 Srinivasan Vijayakumar 1 1Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA 2Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA Received: May 13, 2019 ABSTRACT Revised: Jul 26, 2019 Accepted: Oct 5, 2019 Objective: Primary sarcoma of the cervix is rare and is associated with worse outcomes as Correspondence to compared to other histologies. The purpose of this study was to identify national treatment Ashley Albert patterns and outcomes based on histological subtype using the National Cancer Database (NCDB). Department of Radiation Oncology, University Methods: of Mississippi Medical Center, 350 W. The NCDB was queried for patients with cervical cancer from 2004–2015. Woodrow Wilson Drive, Suite 1600, Jackson, Clinico-demographic treatment details were obtained and compared between patients with MS 39213, USA. squamous cell carcinoma (SCC), adenocarcinoma, and sarcoma of the cervix. Multivariable E-mail: [email protected] Cox regression and the Kaplan-Meier method was used to examine survival. Results: 107,177 patients met inclusion criteria including 81,245 (75.8%) women with SCC, Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of 24,562 (22.9%)
    [Show full text]
  • SMARCA4-Deficient Undifferentiated Uterine Sarcoma
    Modern Pathology (2018) 31:1442–1456 https://doi.org/10.1038/s41379-018-0049-z ARTICLE SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma 1 2 2 2 2 1 David L. Kolin ● Fei Dong ● Michele Baltay ● Neal Lindeman ● Laura MacConaill ● Marisa R. Nucci ● 1 1,3 Christopher P. Crum ● Brooke E. Howitt Received: 13 December 2017 / Revised: 25 January 2018 / Accepted: 4 February 2018 / Published online: 26 April 2018 © United States & Canadian Academy of Pathology 2018 Abstract Small cell carcinoma of the ovary, hypercalcemic type is a rare, aggressive malignancy which usually occurs in young women and is characterized by mutations in SMARCA4, with few other alterations. We recently encountered uterine tumors with morphologic, immunohistochemical, and genetic similarities to small cell carcinoma of the ovary, hypercalcemic type. Herein we report the clinicopathologic and molecular features (using a targeted massively parallel sequencing [MPS] assay) of these tumors. The cases were diagnosed on cervical and endometrial biopsies (n = 2, 34, and 29 years) or hysterectomy 1234567890();,: 1234567890();,: and bilateral salpingo-oophorectomy (n = 3, 25, 33, and 58 years). The tumors were composed of sheets of large atypical epithelioid cells with prominent rhabdoid morphology, indistinguishable from the “large cell” variant of small cell carcinoma of the ovary, hypercalcemic type. In three cases, the ovaries were pathologically examined to exclude a primary ovarian malignancy. Immunohistochemically, four of four cases showed SMARCA4 loss, and were negative or only focally positive for keratins, EMA, and claudin-4. One of three cases was positive for WT-1.
    [Show full text]